Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2016

View Archived Issues

Apixaban equivalent to warfarin in AF patients with cancer

Seattle Genetics initiates phase I study of SGN-CD123A for relapsed/refractory AML

Galenica completes acquisition of Relypsa

BioPontis Alliance for Rare Diseases and VIB enter a strategic partnership

Merck & Co. discontinues development of odanacatib for osteoporosis

Novartis describes discovery of novel PI3Kdelta inhibitor CDZ-173

Allergan studies oral ubrogepant for acute treatment of migraine in phase III

Opsona Therapeutics' OPN-305 granted FDA orphan drug status

GSK initiates phase IIa trial of shigella vaccine in Kenya

ASLAN Pharmaceuticals licenses RON antibody from A*STAR

Amgen obtains global rights to BI-836908 from Boehringer Ingelheim

CADPA biomarker algorithm identifies asymptomatic patients at risk for cardiac events

NIH funds six projects seeking to identify biological factors that influence neural regeneration

Central administration of donepezil improves long-term heart failure prognosis in vivo

Dynavax provides update on recent dialogue with FDA regarding Heplisav-B BLA

Glucox Biotech describes novel NADPH oxidase 4 inhibitors

Bayer Pharma patents Wnt signaling pathway inhibitors

FDA extends IDegLira NDA review

GenSight Biologics' GS-030 receives orphan drug designation and ATMP classification in Europe

Suzhou Zelgen Biosciences presents new farnesoid X receptor agonists

Shanghai De Novo Pharmatech identifies novel IDO1/TDO2 inhibitors

Guangzhou Institutes of Biomedicine and Health divulges UCP 1 activators

New phase II trial assesses CD24Fc for prevention of GvHD

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical generate anti-HER2 antibody-drug conjugate

Genentech reports positive results from phase III OAK study of atezolizumab

New class of FBPase 1 inhibitors identified at Chinese Academy of Medical Sciences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...